A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

PURPOSE: Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment of hematological malignancies (NCT01943851). PATIENTS AND METHODS: Part 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawson, Mark A., Borthakur, Gautam, Huntly, Brian J.P., Karadimitris, Anastasios, Alegre, Adrian, Chaidos, Aristeidis, Vogl, Dan T., Pollyea, Daniel A., Davies, Faith E., Morgan, Gareth J., Glass, Jacob L., Kamdar, Manali, Mateos, Maria-Victoria, Tovar, Natalia, Yeh, Paul, Delgado, Regina García, Basheer, Faisal, Marando, Ludovica, Gallipoli, Paolo, Wyce, Anastasia, Krishnatry, Anu Shilpa, Barbash, Olena, Bakirtzi, Evi, Ferron-Brady, Geraldine, Karpinich, Natalie O., McCabe, Michael T., Foley, Shawn W., Horner, Thierry, Dhar, Arindam, Kremer, Brandon E., Dickinson, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932578/
https://www.ncbi.nlm.nih.gov/pubmed/36350312
http://dx.doi.org/10.1158/1078-0432.CCR-22-1284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932578/
https://www.ncbi.nlm.nih.gov/pubmed/36350312
http://dx.doi.org/10.1158/1078-0432.CCR-22-1284

Ejemplares similares